NCT00585390

Omega-3 Fatty Acid Deficiency Replacement in Early Schizophrenia

Randomized, Double-Blind, Placebo-Controlled Pilot Trial of Essential Fatty Acid Deficiency Replacement in Early Schizophrenia

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: University of Cincinnati · Academic / Other
• Sex: All
• Age: 8 Years – 25 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this research study is to find out what effects (good and bad) that omega-3 fatty acids has on schizophrenia.

Detailed description

The two aims of the study test the hypotheses that correcting omega-3 fatty acid deficiency in the early stages of schizophrenia improves positive symptom treatment response, negative symptom treatment response, and cognition symptom response.

Conditions

• Schizophrenia
• Fatty Acid Deficiency

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Omega-3 Fatty Acids	* Essential omega-3 fatty acid replacement therapy with Eicosapentaenoic acid at 3.2 grams * Docosahexaenoic acid fish oil concentrate at 1.6 grams
OTHER	Olive oil placebo	Olive oil capsules, 8 capsules per day
DIETARY_SUPPLEMENT	EPA fish oil concentrate; DHA fish oil concentrate	3.2 grams for EPA 1.6 grams for DHA
DRUG	Placebo	Olive oil capsule

Timeline

• Start date: 2008-01-01
• Primary completion: 2009-11-01
• Completion: 2009-11-01
• First posted: 2008-01-03
• Last updated: 2011-08-02

Locations

1 site across 1 country: United States